Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2010
11/02/2010US7825135 pyridylpiperidine compounds such as 2-chloro-3,6-difluoro-N-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide, used for the treatment of nervous system and psychological disorders
11/02/2010US7825134 Amelioration of cataracts, macular degeneration and other ophthalmic diseases
11/02/2010US7825133 a mixture of 1-(4-hydroxyphenyl)-5-methylpyridin-2-one and pharmaceutically-acceptable excipients, used foro the treatment of liver fibrosis
11/02/2010US7825132 administering fibroblast growth factor receptor 3 (FGFR3) inhibitors such as 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one, for the treatment of bone disorders in patient with a t(4;14) chromosomal translocation
11/02/2010US7825131 Quinoline potassium channel inhibitors
11/02/2010US7825130 Phosphatase and Tensin homolog deleted on chromosome Ten (PTEN), a tumor suppressor gene or calcium sensitive potassium channel modulators, comprising tetrazolylalkoxy-dihydrocarbostyril compounds such as Cilostazol , used for the treatment of Alzheimer's disease
11/02/2010US7825129 Thieno[2,3-c] isoquinolines for use as inhibitors of PARP
11/02/2010US7825128 such as N-(ethoxycarbonyl)-S-(4-{[4-{[(R)-2-hydroxy-1-methylethyl]amino}-5-(2-thienyl)pyrimidine-2-yl]amino}phenyl)-S-methylsulfoximide, used for the treatment of breast cancer and rheumatoid arthritis
11/02/2010US7825127 Administering N-{2-[4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethyl}-3-hydroxy-3-methylbutanamide;reduced toxicity or extremely few side effects; breast, prostate, lung, kidney cancer
11/02/2010US7825126 (N)-methanocarba adenine nucleosides contemplated for use in the treatment a number of diseases, for example, inflammation, cardiac ischemia, stroke, asthma, diabetes, cardiac arrhythmias and cardioprotection
11/02/2010US7825125 Amorphous aripiprazole and process for the preparation thereof
11/02/2010US7825124 Indolylmaleimide derivatives
11/02/2010US7825123 Isoxazolo[4,5]pyridin-3-yl-piperazin derivatives useful as modulators of dopamine D3 receptors
11/02/2010US7825122 Diaza heterocyclic sulfonamide derivatives and their uses
11/02/2010US7825121 useful as selective CCR5 antagonists; use of a combination of a CCR5 antagonist of this invention and one or more antiviral or other agents in the treatment of HIV
11/02/2010US7825120 tert-butyl 4-{[3-({[(6-methyl-3-pyridyl)amino]carbonylamino}methyl)phenyl]methyl}-piperazinecarboxylate; selectively modulates the cardiac sarcomere, for example by potentiating cardiac myosin, and may be useful in the treatment of systolic heart failure including congestive heart failure
11/02/2010US7825119 Bone disorders such as osteoporosis, tumors and cardiovascular disorders; 4-(2-carboxy-2-Boc-aminoethylamino)-6-piperidinopyrimidines such as tert-butyl 2-benzyloxycarbonylamino-3-[2,5-dimethoxy-6-(4-[1,8]naphthyridin-2-yl-piperidin-1-yl)pyrimidin-4-ylamino]-propionate
11/02/2010US7825118 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcinogenic and antiinflammatory agents
11/02/2010US7825117 administering prokineticin 1 receptor antagonists such as N-{2-[5-(4-Ethyl-benzyl)-1-(4-methoxy-benzyl)-4,6-dioxo-1,4,5,6-tetrahydro-[1,3,5]triazin-2-ylamino]-ethyl}-guanidine, to treat inflammation in the intestines, irritable bowel syndrome, inflammatory bowel disease or Crohn's disease
11/02/2010US7825116 N2, N4-bis-aryl-5-fluoro-2,4-pyrimidinediamines
11/02/2010US7825115 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate
11/02/2010US7825114 Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
11/02/2010US7825113 2-oxy-benzoxazinone derivatives for the treatment of obesity
11/02/2010US7825112 antagonists to the effect of chemokines such as 4-((S)-1-cyclopropylpiperidin-3-ylmethyl)piperazine-1-carboxylic acid [4-(5-cyclohexyl-2-methoxyphenyl)thiazol-2-yl]amide, used for treating acute and chronic immuno-inflammatory diseases, viral or bacterial infections and bone disorders
11/02/2010US7825111 Substituted spiroheterocycles
11/02/2010US7825110 Substituted spiroheterocycles
11/02/2010US7825109 Compound capable of binding S1P receptor and pharmaceutical use thereof
11/02/2010US7825107 administering to a patient in need thereof an effective amount of fispemifene wherein said chronic nonbacterial prostatitis is not associated with urethral sphincter dysfunction
11/02/2010US7825106 Modified release formulations and methods of treating inflammatory bowel disease
11/02/2010US7825105 such as 3,10-Dibenzyloxyminocycline, used to treat bacterial infections and neoplasms, as well as blocking tetracycline efflux and modulation of gene expression
11/02/2010US7825104 phenylboronic acid, or water soluble derivative thereof
11/02/2010US7825103 5'-O-triisopropylsilyl-2'-cyano-2'-deoxy-1- beta -D-arabinofuranosylcytosine; antitumor agents
11/02/2010US7825102 administering adenosine receptor agonists such as N6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide; vision defects
11/02/2010US7825101 introducing into cell a double stranded siNA that cleaves MLCK RNA, wherein each strand of siNA molecule is 19-25 nucleotides in length and one strand of siNA molecule comprises a region having a nucleotide sequence having complementarity to MLCK RNA for siNA molecule to direct cleavage of MLCK RNA
11/02/2010US7825098 promoting brown adipocyte differentiation by contacting a preadipocyte or a white adipocyte with a small interfering RNA (siRNA) that binds specifically to an mRNA encoding Necdin, wherein the siRNA selectively inhibits Necdin expression in an amount sufficient to increase Uncoupling Protein-1 expression
11/02/2010US7825097 Nucleotide vector vaccine for immunization against hepatitis
11/02/2010US7825096 such as O6-[(3-aminomethyl)benzyl]guanine, used for enhancing the chemotherapeutic treatment of tumor cells in a mammal with an antineoplastic alkylating agent that causes cytotoxic lesions at the O6-position of guanine
11/02/2010US7825095 Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
11/02/2010US7825094 the sensitivity of cells typical of various proliferative disorders to the ansamycin CNF-101 ("17-AAG") is proportional to the HER-2 levels in those cells
11/02/2010US7825084 human dietary supplement, comprising beta-alanine in unit dosage; regulating hydronium ion concentration; increasing beta-alanylhistidine dipeptide; insulin
11/02/2010US7825080 Aqueous solution of olanexidine, method of preparing the aqueous solution, and disinfectant
11/02/2010US7824851 With purine or pyrimidine base; for use in combination with drugs that induce mutation in Flaviviridae at location other than mutation of nucleotide that results in change from serine to a different amino acid in highly conserved consensus sequence XRXSGXXXT of domain B of the RNA polymerase region
11/02/2010US7824745 Benzochromene derivatives
11/02/2010US7824717 Use of licochalcone A against rosacea
11/02/2010US7824713 Method for treating diaper rash using superhydrated bacteriostatic topical preparation with stable acid pH
11/02/2010US7824710 slurrying salt formation, crystallization
11/02/2010US7824709 Bioactive agent delivery particle comprising a lipid binding polypeptide, a lipid bilayer, and a bioactive agent, wherein interior of lipid bilayer comprises a hydrophobic region, and wherein bioactive agent is associated with hydrophobic region of lipid bilayer
11/02/2010US7824707 Backing and reservoir layers with drug; adhered over a prolonged period continuously to surface of skin; time-release agents; drug delivery
11/02/2010US7824706 synergistic efficacy; polar lipid supplement, a soluble fiber, and a nutricine such as threonine
11/02/2010US7824705 Physiologically active agents containing vicinal dithioglycols and use thereof in various branches of economy
11/02/2010US7824704 Controlled release bioactive agent delivery device
11/02/2010US7824698 Lyophilized formulations of Salinosporamide A
11/02/2010US7824696 Modified nucleotides for immunotherapy; induce immunology response; consisting of nucleoside methylphosphonate and 2'-O-methyl-ribonucleoside groups
11/02/2010US7824688 Glucan-based vaccines
11/02/2010US7824687 Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof
11/02/2010CA2686545C Deuterated morpholinyl compounds
11/02/2010CA2623449C A novel use of bivalirudin in the treatment of acute coronary syndrome
11/02/2010CA2611181C Agent for inhibiting visceral fat accumulation
11/02/2010CA2600510C Crystal forms of an imidazole derivative
11/02/2010CA2545527C Pyrazole derivatives as inhibitors of receptor tyrosyne kinases
11/02/2010CA2497544C Pyrazolo[1,5-a]pyrimidines compounds as cyclin dependent kinase inhibitors
11/02/2010CA2494361C Hot melt tts for administering rotigotine
11/02/2010CA2485201C Camptothecins with a modified lactone ring
11/02/2010CA2484542C Method for the inhibition of atrophy or for treatment or prevention of atrophy-related symptoms in women
11/02/2010CA2470391C N,n'-disubstituted piperazine compounds and their use as analgesics
11/02/2010CA2462799C Pyrimidine derivatives
11/02/2010CA2460144C Pyridinic sulfonamide derivatives, method of production and use thereof
11/02/2010CA2460121C 3-substituted-4-pyrimidone derivatives
11/02/2010CA2457720C Medicine containing pyrimidine derivative
11/02/2010CA2457097C Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
11/02/2010CA2455416C Vinca alcaloids preparations process and their derivatives
11/02/2010CA2451798C Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
11/02/2010CA2448244C Use of the acetyl l-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus
11/02/2010CA2446639C Composition for the prevention of addiction in pain management
11/02/2010CA2439784C Pyrazolopyrimidinone derivatives having pde7 inhibiting action
11/02/2010CA2437715C Carboline derivatives
11/02/2010CA2437481C The use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body
11/02/2010CA2436361C Angiotensin ii antagonistic compound for use as analgesic and antiinflammatory agent
11/02/2010CA2417432C Modified polypeptides stabilized in a desired conformation and methods for producing same
11/02/2010CA2416771C 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid for treatment of cox-2 dependent disorders
11/02/2010CA2415869C Sprayable wound care compositions comprising gellan gum
11/02/2010CA2413971C Heterocyclic hydrazones as novel anti-cancer agents
11/02/2010CA2407466C Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
11/02/2010CA2405741C Sodium salt of an azo derivative of 5-aminosalicylic acid
11/02/2010CA2393523C Combination of cyamemazine and an atypical neuroleptic
11/02/2010CA2389681C Npy y5 antagonist
11/02/2010CA2389491C Spiro(2h-1-benzopyran-2,4'-piperidine) derivates as glycine transport inhibitors
11/02/2010CA2383293C Anti-infective compositions for treating disordered tissue such as cold sores
11/02/2010CA2341281C Sustained-release anti-parasitic compositions comprising macrolides
11/02/2010CA2337422C Preventing airway mucus production by administration of egf-r antagonists
11/02/2010CA2336602C Companion animal therapeutic treat
11/02/2010CA2318348C Pharmaceutical composition comprising at least one aminopeptidase a inhibitor
11/02/2010CA2311456C Imidazonaphthyridines and their use in inducing cytokine biosynthesis
11/02/2010CA2257607C The use of l-lysine in the treatment of hair loss
11/02/2010CA2253246C Purified multimerase
11/02/2010CA2225998C Gene preparations containing biocompatible material for sustained release in gene therapy
11/02/2010CA2225713C Pharmaceutical compositions containing herbal-based active ingredients; method for preparing same and uses of same for medical and veterinary purposes
10/2010
10/30/2010CA2668580A1 Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
10/28/2010WO2010124283A2 Methods and compositions relating to hematologic malignancies
10/28/2010WO2010124237A1 Methods of treating infections of the nail
1 ... 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 2044 2045 2046 ... 7860